SelectScience
Join Free
Accelerating Science
NewsLife Sciences

TriLink BioTechnologies partners with Imperial College London to produce saRNA for COVID-19 vaccine development

TriLink BioTechnologies
9 Jun 2020
Tom Casburn
Associate Editor

Industry news

TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, have entered into a partnership in which TriLink will manufacture self-amplifying RNA (saRNA) for COVID-19 vaccine development. The vaccine development program is led by Professor Robin Shattock, Head of Mucosal Infection and Immunity within the Department of Infectious Disease at Imperial.

Under this development partnership, TriLink will use its robust RNA manufacturing capabilities to respond to the global need for vaccine support against COVID-19. TriLink is a pioneering manufacturer of GMP RNA (mRNA and saRNA) and can scale production from research to clinical development, allowing for efficient RNA production from a single source.

“As pioneering manufacturers of GMP-grade mRNA, TriLink is committed to working alongside our partners to rapidly respond and prioritize the development of a COVID-19 vaccine,” commented Carl Hull, CEO of Maravai LifeSciences. “The health and safety of the global population is the basis of the collaboration with Imperial College London. The opportunity to bring accelerated RNA manufacturing to vaccine development for this global crisis is deeply engrained in our mission to bring the miracles of science to life.”

“We are committed to the rapid development of our saRNA vaccine against COVID-19,” commented Prof. Robin Shattock. “Our partnership with TriLink is critical to this process and ensures our ability to rapidly move our vaccine into clinical testing. The significant dose sparing nature of saRNA provides capability to rapidly scale the manufacture to millions of doses. We are driven to contribute to the global effort to develop and scale prophylactic vaccines capable of impacting on this pandemic.”

The vaccine development by Imperial through Prof. Shattock is focused on the urgent COVID-19 response, and TriLink is poised to deliver saRNA manufacturing capabilities up to a Phase II scale. TriLink has also been awarded an additional partnership with Imperial for the development of two additional virus targets — Marburg and Rabies.

For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>

Links

TriLink BioTechnologies

Tags

ImmunologyImmunological techniques measure and characterize immune responses. Immunology kits and analysis systems often use techniques such as ELISA, radioimmunoassay (RIA) and immunodiffusion assays, Immunohistochemistry, and flow cytometry. Immunologists use equipment such as flow Cytometers, plate readers, plate washers and fluorescent microscopes.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.DNA / RNA QuantificationDetection and quantification of nucleic acids is important in molecular biology, cloning, expression, forensics and clinical diagnostics. Nucleic acids can be detected by labeling with colorimetric, fluorescent or radio labels and using in situ hybridization kits to identify specific sequences. Multiple nucleic acids can be detected and quantified at once using RNA / DNA detection beads or RNA / DNA microarrays. Find the best DNA / RNA Quantification products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.RNARNA is a nucleic acid that plays a key role in gene expression and protein synthesis. It serves as a messenger between DNA and ribosomes, carrying genetic instructions to produce proteins. Advances in RNA-based therapies, such as mRNA vaccines and gene editing, have revolutionized treatment strategies for genetic disorders and infectious diseases. Explore RNA research tools and therapies in our peer-reviewed product directory; compare products, check customer reviews, and get pricing directly from manufacturers.Vaccine DevelopmentVaccine development focuses on creating immunizations to protect against infectious diseases. The process involves identifying antigens, developing and testing vaccine efficacy, and ensuring safety through preclinical testing and multiple clinical trial phases. Scientists use various approaches, including weakened or inactivated viruses, protein subunits, or mRNA. Advanced platforms and rapid diagnostic tools aid in vaccine research and testing. Explore vaccine development solutions in our peer-reviewed product directory; compare products, read reviews, and get pricing directly from manufacturers. Covid-19COVID-19, caused by the SARS-CoV-2 virus, has led to a global health crisis with profound impacts on societies and economies. Research into diagnostics, vaccines, treatments, and understanding viral mechanisms continues to evolve. The pandemic has accelerated innovations in healthcare and biopharmaceuticals, including novel vaccine platforms and rapid testing technologies. Browse our peer-reviewed product directory to find top COVID-19 testing kits, research tools, vaccines, and treatments, compare products, read reviews, and receive direct pricing from manufacturers.

Related articles

TriLink BioTechnologies partners with Imperial College London to produce saRNA for COVID-19 vaccine development